An FDA advisory panel on Aug. 10 will review a de novo classification petitionfrom Baebies Inc. for its newborn screening device to detect lysomal storage disorders, and the advisors are expected to focus closely on the false-positive rate for the test seen in a pivotal study.
Specifically, the firm's Seeker Systemand Seeker Reagent Kitwasdeveloped to detect reduced levels of multiple lysomal enzymes in infants based on dried blood samples. There is currently no screening test that has been cleared in the US to screen babies with lysomal storage disorders, and Baebies' offering might fill an important medical gap
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?